AVTX
Avalo Therapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeAvalo reported Q3 2026 narrowed losses and maintains $462.8M cash runway into 2029, but the company faces significant clinical and strategic headwinds: a wave of analyst downgrades in late October citing IL-1 program concerns triggered a 44% stock plunge, and management is actively exploring strategic alternatives and pipeline pruning to streamline operations. The Phase 3 program initiation now hinges on FDA feedback expected by year-end 2026, creating near-term binary risk.
Red flags
- •Wave of analyst downgrades (H.C. Wainwright downgrade to Neutral, Wedbush price target cut from $34 to $22) in October 2026 citing IL-1 program clinical concerns
- •Stock plunged ~44% over five sessions following downgrades, indicating loss of investor confidence
- •Company exploring 'strategic alternatives' for lead asset AVTX-010 and pipeline pruning, signaling potential pivot or asset sales under pressure
- •Phase 3 program initiation delayed to H1 2027 pending FDA feedback expected by year-end 2026 (binary event risk)
- •Implicit clinical trial setback or development plan concerns driving analyst downgrades, though specific trial data not disclosed
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 1.6M | $25M |
Quarter-end 13F positions for the tracked funds holding this stock.